The complement system in the pathogenesis and progression of kidney diseases: What doesn't kill you makes you older

被引：4

作者：

Stea, Emma Diletta ^{[1
]}

D'Ettorre, Giuseppina ^{[2
]}

Mitrotti, Adele ^{[1
]}

Gesualdo, Loreto ^{[1
]}

机构：

[1] Univ Bari Aldo Moro, Dept Precis & Regenerat Med & Ionian Area DiMePre, Nephrol & Urol Units, Bari, Italy

[2] SS Annunziata Hosp, Nephrol Unit, Taranto, Italy

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2024年 / 124卷

关键词：

Complement System; Renal diseases; Glomerulonephritis; Lupus nephritis; atypical Hemolytic Uremic Syndrome; Complement inhibitors; IDIOPATHIC MEMBRANOUS NEPHROPATHY; ANTIBODY-ASSOCIATED VASCULITIS; TO-MESENCHYMAL TRANSITION; DONOR BRAIN-DEATH; POSTINFECTIOUS GLOMERULONEPHRITIS; GLOMERULAR DEPOSITION; C3; GLOMERULOPATHY; FACTOR-H; ISCHEMIA/REPERFUSION INJURY; EPITHELIAL-CELLS;

D O I：

10.1016/j.ejim.2024.02.015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Complement System is an evolutionarily conserved component of immunity that plays a key role in host defense against infections and tissue homeostasis. However, the dysfunction of the Complement System can result in tissue damage and inflammation, thereby contributing to the development and progression of various renal diseases, ranging from atypical Hemolytic Uremic Syndrome to glomerulonephritis. Therapeutic interventions targeting the complement system have demonstrated promising results in both preclinical and clinical studies. Currently, several complement inhibitors are being developed for the treatment of complementmediated renal diseases. This review aims to summarize the most recent insights into complement activation and therapeutic inhibition in renal diseases. Furthermore, it offers potential directions for the future rational use of complement inhibitor drugs in the context of renal diseases.

引用

页码：22 / 31

页数：10